Hemostasis Products Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The hemostasis products market size has grown strongly in recent years. It will grow from $1.7 billion in 2024 to $1.81 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rise in surgical procedures, growing aging population, increasing incidence of hemophilia, expanding healthcare infrastructure, rising awareness about blood clotting disorders.

The hemostasis products market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising demand for minimally invasive surgeries, global increase in trauma cases, expansion of hemostasis applications in chronic diseases, shift towards ambulatory surgical centers, personalized medicine and biomarker research. Major trends in the forecast period include technological innovations in hemostasis, advancements in hemostatic technologies, rising preference for minimally invasive procedures, growing incidence of chronic diseases, focus on biodegradable hemostatic agents.

The growing prevalence of blood disorders is anticipated to drive the growth of the hemostasis products market in the future. Blood disorders, also referred to as hematologic disorders, encompass a range of medical conditions that impact the composition, function, and behavior of blood and its components. Hemostasis products are utilized in various blood disorders to help manage the processes of clotting and bleeding in the body, addressing both excessive bleeding (hemorrhage) and excessive clotting (thrombosis) that can arise in different blood disorders. For example, in 2022, the Leukemia and Lymphoma Society, a U.S.-based organization, reported that the rate of leukemia diagnoses in the United States rose from 14.1 per 100,000 citizens in 2021 to 14.3 per 100,000 in 2022. Consequently, the increasing prevalence of blood disorders is fueling the growth of the hemostasis products market.

The rising prevalence of cardiac disorders is expected to propel the growth of the hemostasis products market moving forward. Cardiac disorders encompass a wide range of medical conditions and diseases that impact the heart and blood vessels. Hemostasis products play a critical role in managing bleeding related to cardiac disorders, as well as in their prevention and treatment. These products can help minimize blood loss, thereby reducing the need for blood transfusions and the associated complications in cardiac disorders. For instance, in January 2024, the American Heart Association, a U.S.-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, reflecting a 4% increase from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiac disorders is contributing to the growth of the hemostasis products market going forward.

Major companies in the hemostasis products market are focusing on the development of innovative drugs, including the Nexpowder endoscopic hemostasis system, and obtaining approvals for a comprehensive range of active and passive hemostatic products for bleeding control. The endoscopic hemostasis system is a medical device and technique used to control bleeding in the gastrointestinal (GI) tract during endoscopic procedures. Medtronic plc, a US-based medical device company, received clearance from the U.S. Food and Drug Administration in September 2022 for the Nexpowder Endoscopic Hemostasis System, designed for the treatment of nonvariceal upper GI bleeding. This innovative hemostatic product has the potential to make a significant impact on the treatment of nonvariceal upper GI bleeding due to its ease of use, effectiveness, and good tolerability.

In March 2022, C2Dx Inc., a U.S.-based specialty medical devices company, acquired Hemostatix Medical Technologies LLC for an undisclosed sum. This acquisition supports C2Dx's strategy to invest in and enhance the delivery of valuable niche products, facilitating the integration of the thermal scalpel system under the C2Dx brand. Hemostatix Medical Technologies LLC is also a U.S.-based medical technology company.

Major companies operating in the hemostasis products market report are Pfizer Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Medtronic PLC, Johnson And Johnson Pvt. Ltd., Siemens Healthineers, Becton Dickinson and Company (BD), Stryker Corporation, Baxter International Inc., Boston Scientific Corporation, F. Hoffmann-La Roche Ltd., BBraun Melsungen AG, Fresenius Kabi AG, Zimmer Biomet Holdings Inc., Olympus Corporation, Grifols S.A., Terumo BCT Inc., Smith And Nephew PLC, Ethicon Suture Laboratories, Hologic Inc., Cook Medical, Teleflex Incorporated, Integra LifeSciences Corporation, Haemonetics Corporation, Z-Medica LLC, Tricol Biomedical, Hem Con Medical Technologies Inc., Hemostasis LLC, C. R. Bard Inc., CuraMedical BV.

North America was the largest region in the hemostasis products market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemostasis products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemostasis products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hemostasis products market consists of sales of hemostatic agents, hemostatic powders, hemostatic sponges, collagen, oxidized regenerated cellulose, gelatin, polysaccharide, flowable complex, thrombin complex, fibrin complex, synthetic sealants, and fresh frozen plasma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Hemostasis products are medical substances or devices employed to control bleeding and facilitate clotting (hemostasis) across diverse medical contexts. These products play a critical role in the management of bleeding disorders, promotion of wound healing, and ensuring the proper functioning of the body's clotting mechanisms.

The primary categories of hemostasis products include topical hemostasis products, infusible hemostasis products, and advanced hemostasis products. Topical hemostasis products encompass medical substances or materials specifically designed to halt or regulate bleeding. They find applications in various scenarios such as trauma, surgery, hemophilia, myocardial infarction, and others, with major end-users including hospitals, clinics, and others.

The hemostasis products market research report is one of a series of new reports that provides hemostasis products market statistics, including hemostasis products industry global market size, regional shares, competitors with a hemostasis products market share, detailed hemostasis products market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis products industry. This hemostasis products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.